Author: courtneys

Spear Bio’s SPEAR UltraDetect™ BD-pTau 217 Assay Named a 2026 R&D 100 Award Winner

Prestigious R&D 100 Award recognizes Spear Bio’s innovation in ultra-sensitive measurement of brain-derived pTau 217 in plasma WOBURN, Mass.–(BUSINESS WIRE)– Spear Bio, a biotechnology company pioneering wash-free ultrasensitive immunoassay technology, today announced that its SPEAR UltraDetect™ BD-pTau 217 Assay has received a 2026 R&D 100 Award. Presented annually by R&D World, the awards recognize 100 of […]

Read More

Spear Bio to Unveil Novel Alzheimer’s Disease Immunoassays and Fully Automated Instrument Platform at AAIC 2026

Launches include the first commercially available singleplex eMTBR-Tau immunoassay, a novel pTau 217 assay for venous and capillary blood, and a fully automated instrument platform WOBURN, Mass.–(BUSINESS WIRE)–Spear Bio, an innovator in ultrasensitive protein biomarker detection, today announced plans to unveil new SPEAR immunoassay and instrument innovations at the Alzheimer’s Association International Conference® 2026, taking […]

Read More

Meet Spear Bio at AAIC 2026

Discover new SPEAR UltraDetect™ assay and instrument innovations for Alzheimer’s and neurodegenerative biomarker research Spear Bio is excited to exhibit at the Alzheimer’s Association International Conference® 2026 in London. Visit us at Booth 322 to learn how SPEAR immunoassays are advancing ultra-sensitive, low-volume biomarker measurement across Alzheimer’s disease, neurodegeneration, and preclinical research. At AAIC 2026, Spear Bio will introduce […]

Read More

Enhance Neurodegenerative Detection and Monitoring with BD-pTau 217 and α-Syn

Tuesday, May 12, 2026 | 11am EDT (NA) / 4pm BST (UK) / 5pm CEST (EU-Central) The ability to reliably detect blood-based biomarkers such as brain-derived pTau 217 (BD-pTau 217) and α-synuclein species across healthy and disease populations has remained a significant challenge in neurodegenerative disease research. Recent advances in ultra-sensitive immunoassay technology are now […]

Read More

Spear Bio Introduces New Ultra-Sensitive Neurodegenerative Assays and Expands Direct Access at AD/PD 2026

WOBURN, Mass.–(BUSINESS WIRE)–Spear Bio, an innovator in ultrasensitive protein biomarker detection, showcased three new SPEAR UltraDetect™ immunoassays—brain-derived p-Tau 217 (BD-pTau 217), α-synuclein (α-syn) and phospho-Ser129-α-synuclein (pS129-α-syn)—at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2026) last week. The product debuts coincide with the company’s newly established direct-to-customer operations in North America and Europe, an important step that will […]

Read More

AD/PD™ Alzheimer’s & Parkinson’s Diseases Conference 2026

Join Spear Bio at AD/PD™ 2026Spear Bio is proud to sponsor and participate in AD/PD™ 2026: International Conference on Alzheimer’s and Parkinson’s Diseases, taking place in Copenhagen, Denmark, from March 17-21, 2026.  This conference is where the brightest minds gather to explore the latest research, clinical trials, and treatments for Alzheimer’s and Parkinson’s. From uncovering groundbreaking discoveries to […]

Read More

GAP-Net Site Optimization Conference 2026

As the largest North American network of private and institution-based neurodegenerative disease clinical trial sites, the annual GAP-Net Site Optimization conference offers a unique interaction and multi-directional dialogue among all partners. The reciprocal communication experienced by attendees is critical to the success of the clinical trials we conduct, offering opportunities for people involved in all […]

Read More

Alzheimer’s & Parkinson’s Drug Development Summit

February 3-5, 2026 | Boston, MA The approval of the first anti-amyloid drugs has resurrected the neurodegenerative disease space, opening the door for enhanced competition and innovation to develop novel disease-modifying therapies. However, as challenges remain in the clinical adoption of Lecanemab and Donanemab, the field needs to navigate the move towards disease-modifying therapeutics. Capitalizing […]

Read More

Enhanced early Alzheimer’s detection with the novel SPEAR UltraDetect pTau 217 Assay

Friday, January 30 at 10:00 EST | 07:00 PST | 15:00 GMT | 16:00 CET This SelectScience webinar will highlight how the SPEAR UltraDetect™ platform enables ultra-sensitive and highly specific detection of plasma pTau 217 for enhanced accuracy of early Alzheimer’s detection.  Attendees will gain an overview of how SPEAR UltraDetect pTau 217 performance compares […]

Read More

Formulatrix® and Spear Bio Advance Automated Ultrasensitive Protein Detection Through Ongoing Partnership

Bedford, MA, January 15, 2026 — Formulatrix, a leader in laboratory automation solutions, and Spear Bio, an innovator in ultrasensitive protein biomarker detection, today announced their ongoing partnership to automate and optimize the SPEAR UltraDetect™ assay platform using the F.A.S.T.™ (Flow Axial Seal Tip) Liquid Handler. This partnership combines Spear Bio’s next-generation immunoassay technology with Formulatrix’s […]

Read More